Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mefenamic acid + paracetamol (Blue Cross Laboratories)
- Development stage
- Phase 2
- Lead developer
- Blue Cross Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Meftal-Forte is a combination analgesic and antipyretic medication containing mefenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), and paracetamol (acetaminophen). Developed and marketed by Blue Cross Laboratories, it is widely used for the short-term relief of mild to moderate pain, inflammation, and fever. Mefenamic acid works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the synthesis of inflammatory prostaglandins. Paracetamol acts primarily on the central nervous system to increase the pain threshold and regulate body temperature via the hypothalamic heat-regulating center. Meftal-Forte is commonly prescribed for menstrual cramps (dysmenorrhea), dental pain, headaches, muscle aches, and post-operative pain.
- Brand names
- Meftal-ForteMeftal-Forte Junior
- Other names
- mefenamic acid + acetaminophenmefenamic acid and acetaminophenmefenamic acid and paracetamolmefenamic acid/acetaminophenmefenamic acid/paracetamol
02
Targets
PTGER (Prostaglandin E2 receptor)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on mefenamic acid + paracetamol (Blue Cross Laboratories).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mefenamic acid + paracetamol (Blue Cross Laboratories).